Overview:

Summary

The industry analysis specialist, has released its new report, “Gout Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global gout market. The report identifies the key trends shaping and driving the global gout market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global gout sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData has estimated the global gout therapeutics market to be valued at $854 million in 2010. It is forecast to grow at a CAGR (Compound Annual Growth Rate) of 12% for the next seven years to reach $1.8 billion by 2017. The market grew at a CAGR of 7% during the historic period (2005-2010). The major breakthrough in the otherwise dormant gout market was the approval of Uloric (febuxostat) after 40 years by the EMEA (European Medicines Agency) in 2008 and by the FDA (Foods and Drug Administration) in 2009. Krystexxa also got approval in September 2010, for the treatment of refractory gout. The increasing patient population and expected launch of few biologics and newer therapies during the forecast period will drive the market growth.

Scope

The report provides information on the key drivers and challenges of the gout market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) gout market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as Interleukin-1 (IL-1) blocker, monoclonal antibody, purine nucleoside phosphorylase (PNP) inhibitor and URAT1 inhibitors (urate-anion exchanger).
- Analysis of the current and future competition in the seven key countries gout market. Key market players covered are Novartis AG, Regeneron Pharmaceuticals, Ardea Biosciences, Nuon Therapeutics, Metabolex, Inc and BioCryst Pharmaceuticals
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the gout therapeutics market.
- Analysis of key recent licensing and partnership agreements in gout market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global gout market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global gout market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global gout market landscape? – Identify, understand and capitalize"

Companies Mentioned

"Takeda Pharmaceutical Company Limited
Savient Pharmaceuticals, Inc.
Novartis AG
Regeneron Pharmaceuticals, Inc.
Ardea Biosciences, Inc
BioCryst Pharmaceuticals, Inc.
Nuon Therapeutics, Inc.
Metabolex, Inc

1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 Gout Therapeutics Market: Introduction 6
2.1 Overview 6
2.2 Etiology and Pathophysiology 7
2.3 Signs and Symptoms 8
2.4 Epidemiology 8
2.5 Diagnosis 9
2.6 Treatment and Management Pattern 9
2.7 GlobalData Pipeline Report Guidance 12
3 Gout Therapeutics Market: Market Characterization 13
3.1 Gout Therapeutics, Global, Market Size (2005–2010) 13
3.2 Global, Market Forecast (2010-2017) 14
3.3 The US Market Size (2005-2010) 15
3.4 The US Market Forecast (2010–2017) 16
3.5 The UK Market Size (2005-2010) 17
3.6 The UK Market Forecast (2010–2017) 18
3.7 Germany Market Size (2005–2010) 19
3.8 Germany Market Forecast (2010–2017) 20
3.9 France Market Size (2005–2010) 21
3.10 France Market Forecast (2010-2017) 22
3.11 Spain Market Size (2005-2010) 23
3.12 Spain Market Forecast (2010–2017) 24
3.13 Italy Market Size (2005-2010) 25
3.14 Italy Market Forecast (2010-2017) 26
3.15 Japan Market Size (2005-2010) 27
3.16 Japan Market Forecast (2010-2017) 28
3.17 Drivers and Barriers for the Gout Therapeutics Market 29
3.17.1 Drivers for the Gout Market 29
3.17.2 Barriers for the Gout Market 30
3.18 Opportunity and Unmet Need 31
3.19 Key Takeaway 32
4 Gout Therapeutics Market: Competitive Assessment 33
4.1 Overview 33
4.2 Strategic Competitor Assessment 33
4.3 Product Profile for the Major Marketed Product in the Gout Therapeutics Market 34
4.3.1 NSAIDs (Nonsteroidal Anti-inflammatory Drugs) 34
4.3.2 Corticosteroids 35
4.3.3 Colcrys 35
4.3.4 Allopurinol 36
4.3.5 Probenecid 37
4.3.6 Uloric, Adenuric (febuxostat) 37
4.3.7 Krystexxa (pegloticase) 38
4.4 Key Takeaway 39
5 Gout Therapeutics: Pipeline Assessment 40
5.1 Overview 40
5.2 Strategic Pipeline Assessment 40
5.3 Gout Market – Pipeline Analysis by Phase of Development 41
5.3.1 Gout – Phase III Clinical Pipeline 41
5.3.2 Gout Market – Phase II Clinical Pipeline 41
5.3.3 Gout Market – Phase I and Pre-Clinical Pipeline 41
5.3.4 Gout Market – Discovery Pipeline 41
5.4 Gout Therapeutics – Pipeline by Mechanism of Action 42
5.5 Technology Trends Analytical Framework 43
5.6 Gout Therapeutics – Most Promising Drugs under Clinical Development 45
5.7 Most Promising Drug Profiles 46
5.7.1 Arcalyst (rilonacept) 46
5.7.2 ACZ885 (Canakinumab) 46
5.7.3 RDEA594 47
5.8 Key Takeaway 48
6 Gout Therapeutics: Clinical Trials Mapping 49
6.1 Clinical Trials by Region/Country (US, EU5 & Japan) 49
6.2 Clinical Trials by Phase of Clinical Development 50
6.3 Clinical Trials by Trial Status 51
6.4 Clinical Trials by Sponsors 52
6.5 Brief Profiles of Top 10 Companies Participating in Clinical Trials 54
7 Gout Therapeutics Market: Strategic Assessment 55
7.1 Key Events Impacting the Future Market 55
7.2 Future Market Competition Scenario 56
8 Gout Market: Future Players 57
8.1 Introduction 57
8.2 Company Profiles 57
8.2.1 Takeda Pharmaceutical Company Limited 57
8.2.2 Savient Pharmaceuticals, Inc. 61
8.2.3 Novartis AG 62
8.2.4 Regeneron Pharmaceuticals, Inc. 68
8.2.5 Ardea Biosciences, Inc 70
8.2.6 BioCryst Pharmaceuticals, Inc. 71
8.2.7 Nuon Therapeutics, Inc. 73
8.2.8 Metabolex, Inc 73
8.3 Details of Other Companies in the Pipeline 74
8.4 Key Takeaway 75
9 Licensing and Partnership Deals 76
10 Gout Market: Appendix 77
10.1 Definition 77
10.2 Acronyms 77
10.3 Research Methodology 78
10.3.1 Coverage 78
10.3.2 Secondary Research 79
10.3.3 Forecasting 79
10.3.4 Primary Research 82
10.3.5 Expert Panel Validation 82
10.4 Contact Us 82
10.5 Disclaimer 82
10.6 Bibliography 83

1.1 List of Tables
Table 1: Gout Therapeutics Market, Global, Revenue ($m), 2005–2010 13
Table 2: Gout Therapeutics Market, Global, Market Forecast ($m), 2010–2017 14
Table 3: Gout Therapeutics Market, The US, Revenue ($m), 2005–2010 15
Table 4: Gout Therapeutics Market, The US, Market Forecast ($m), 2010–2017 16
Table 5: Gout Therapeutics Market, the UK, Revenue ($m), 2005–2010 17
Table 6: Gout Therapeutics Market, the UK, Market Forecast ($m), 2010–2017 18
Table 7: Gout Therapeutics Market, Germany, Revenue ($m), 2005–2010 19
Table 8: Gout Therapeutics Market, Germany, Market Forecast ($m), 2010–2017 20
Table 9: Gout Therapeutics Market, France, Revenue ($m), 2005–2010 21
Table 10: Gout Therapeutics Market, France, Market Forecast ($m), 2010–2017 22
Table 11: Gout Therapeutics Market, Spain, Revenue ($m), 2005–2010 23
Table 12: Gout Therapeutics Market, Spain, Market Forecast ($m), 2010–2017 24
Table 13: Gout Therapeutics Market, Italy , Revenue ($m), 2005–2010 25
Table 14: Gout Therapeutics Market, Italy, Market Forecast ($m), 2010–2017 26
Table 15: Gout Therapeutics Market, Japan, Revenue ($m), 2005–2010 27
Table 16: Gout Therapeutics Market, Japan, Market Forecast ($m), 2010–2017 28
Table 17: Gout Therapeutics Market, Global, Uloric Revenue ($m), 2009–2010 38
Table 18: Gout Therapeutics Market, Phase III Pipeline, 2011 41
Table 19: Gout Therapeutics Market, Phase II Pipeline, 2011 41
Table 20: Gout Therapeutics Market, Phase I and  Pre-Clinical Pipeline, 2011 41
Table 21: Gout Therapeutics Market, Discovery Clinical Pipeline, 2011 41
Table 22: Gout Therapeutics Market, Global, Most Promising Drugs Under Clinical Development, 2011 45
Table 23: Gout Therapeutics, Global, Clinical Trials, 2011 49
Table 24: Gout Therapeutics, Global, Clinical Trials by Phase, 2011 50
Table 25: Gout Therapeutics, Global, Clinical Trials by Status of Development, 2011 51
Table 26: Gout Therapeutics, Global, Prominent Sponsors, 2011 53
Table 27: Gout Therapeutics, Global, Top Ten Companies by Phase, 2011 54
Table 28: Takeda Pharmaceuticals,  Deals, Alliances and Partnerships, 2011 59
Table 29: Takeda Pharmaceuticals, Gout Marketed Products, 2011 61
Table 30: Savient Pharmaceuticals, Deals, Alliances and Partnerships, 2011 62
Table 31: Savient Pharmaceuticals, Gout Marketed Products, 2011 62
Table 32: Novartis AG, Deals, Alliances and Partnership, 2011 64
Table 33: Novartis AG, Gout Pipeline Products, 2011 67
Table 34: Regeneron Pharmaceuticals Inc., Deals, Alliances and Partnership, 2011 69
Table 35: Regeneron Therapeutics  Inc., Gout Pipeline Products, 2011 70
Table 36: Ardea Biosciences  Inc., Deals, Alliances and Partnership, 2011 71
Table 37: Ardea Biosciences  Inc., Gout Pipeline Products, 2011 71
Table 38: BioCryst Pharmaceuticals Inc., Deals, Alliances and Partnership, 2011 72
Table 39: BioCryst Pharmaceuticals Inc., Gout Pipeline Products, 2011 72
Table 40: Nuon Therapeutics  Inc., Deals, Alliances and Partnership, 2011 73
Table 41: Nuon Therapeutics  Inc., Gout Pipeline Products, 2011 73
Table 42: Metabolex  Inc., Deals, Alliances and Partnership, 2011 74
Table 43: Metabolex  Inc., Gout Pipeline Products, 2011 74
Table 44: Description of Other Companies in the Pipeline, 2011 74
Table 45: Gout Therapeutics Market – Deals, 2011 76"

1.2 List of Figures
Figure 1: Gout Therapeutics, 2011 6
Figure 2: Gout Therapeutics, Progression of Disease, 2011 8
Figure 3: Gout Therapeutics Treatment Algorithm, 2011 11
Figure 4: Gout Therapeutics Market, Global, Revenue ($m), 2005–2010 13
Figure 5: Gout Therapeutics Market, Global, Market Forecast ($m), 2010–2017 14
Figure 6: Gout Therapeutics Market, The US, Revenue ($m), 2005–2010 15
Figure 7: Gout Therapeutics Market, The US, Market Forecast ($m), 2010–2017 16
Figure 8: Gout Therapeutics Market, the UK, Revenue ($m), 2005–2010 17
Figure 9: Gout Therapeutics Market, the UK, Market Forecast ($m), 2010–2017 18
Figure 10: Gout Therapeutics Market, Germany, Revenue ($m), 2005–2010 19
Figure 11: Gout Therapeutics Market, Germany, Market Forecast ($m), 2010–2017 20
Figure 12: Gout Therapeutics Market, France, Revenue ($m), 2005–2010 21
Figure 13: Gout Therapeutics Market, France, Market Forecast ($m), 2010–2017 22
Figure 14: Gout Therapeutics Market, Spain, Revenue ($m), 2005–2010 23
Figure 15: Gout Therapeutics Market, Spain, Market Forecast ($m), 2010–2017 24
Figure 16: Gout Therapeutics Market, Italy, Revenue ($m), 2005–2010 25
Figure 17: Gout Therapeutics Market, Italy, Market Forecast ($m), 2010–2017 26
Figure 18: Gout Therapeutics Market, Japan, Revenue ($m), 2005–2010 27
Figure 19: Gout Therapeutics Market, Japan, Market Forecast ($m), 2010–2017 28
Figure 20: Opportunity and Unmet Need in the Gout Therapeutics Market, 2011 31
Figure 21: Strategic Competitor Assessment of the Marketed Products in Gout, 2011 34
Figure 22: Gout Therapeutics Market, Clinical Pipeline by Mechanism of Action (%), 2011 42
Figure 23: Gout Therapeutics Market – Clinical Pipeline by Phase of Development (%), 2011 43
Figure 24: Technology Trends Analytics Framework, 2011 43
Figure 25: Technology Trends Analytics Frame Work – Description, 2011 44
Figure 26: Gout Therapeutics, Global, Clinical Trials by Country, 2011 49
Figure 27: Gout Therapeutics, Global, Clinical Trials by Phase (%), 2011 50
Figure 28: Gout Therapeutics, Global, Clinical Trials by Status of Development (%), 2011 51
Figure 29: Gout Therapeutics, Global, Overall Sponsors (%), 2011 52
Figure 30: Gout Therapeutics, Global, Prominent Sponsors (%), 2011 53
Figure 31: Gout Therapeutics, Global, Top Ten Companies by Phase, 2011 54
Figure 32: Gout Therapeutics Market, Drivers and Restraints, 2011 55
Figure 33: Implications for Future Market Competition in the Gout Therapeutics Market, 2011 56
Figure 34: Gout Therapeutics Market, Clinical Pipeline by Company, 2011 57
Figure 35: GlobalData Market Forecasting Model 81